Septerna (SEPN) caught attention after announcing third quarter results that revealed a substantial jump in sales and a move from last year's losses to positive net income. This signals a noteworthy ...
Septerna, Inc. recently reported third-quarter 2025 earnings, revealing a surge in sales to US$21.5 million and a shift from a net loss to net income compared to the same period last year. Following ...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
The average one-year price target for Septerna (NasdaqGM:SEPN) has been revised to $28.22 / share. This is an increase of 20.29% from the prior estimate of $23.46 dated November 7, 2025. The price ...
Septerna and Novo are currently collaborating on five GPCR targets, with four programs already in progress, representing what Cantor Fitzgerald describes as a potentially multi-billion-dollar ...
Septerna Inc stock reached an all-time high of 29.06 USD, marking a significant milestone for the company. This peak comes amidst a notable 1-year change of 23.4%, reflecting strong investor ...
(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback